{"organizations": [], "uuid": "66541b82ed14ad0da1ca7790a20a746798376908", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-verastem-presents-preclinical-data/brief-verastem-presents-preclinical-data-highlighting-the-effects-of-duvelisib-in-combination-with-immune-checkpoint-or-co-stimulatory-antibodies-in-b-cell-lymphoma-model-idUSFWN1PL18P", "country": "US", "domain_rank": 408, "title": "BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-26T22:34:00.000+02:00", "replies_count": 0, "uuid": "66541b82ed14ad0da1ca7790a20a746798376908"}, "author": "", "url": "https://www.reuters.com/article/brief-verastem-presents-preclinical-data/brief-verastem-presents-preclinical-data-highlighting-the-effects-of-duvelisib-in-combination-with-immune-checkpoint-or-co-stimulatory-antibodies-in-b-cell-lymphoma-model-idUSFWN1PL18P", "ord_in_thread": 0, "title": "BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model", "locations": [], "entities": {"persons": [{"name": "duvelisib", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "verastem inc", "sentiment": "none"}, {"name": "verastem inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "cell lymphoma model reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News January 26, 2018 / 8:37 PM / in 4 minutes BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model Reuters Staff 1 Min Read \nJan 26 (Reuters) - Verastem Inc: \n* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL \n* VERASTEM - DATA SUPPORT EXPLORATION OF DUVELISIB IN COMBINATION WITH ANTI-PD-1/PD-L1 OR CO-STIMULATORY ANTIBODIES IN PATIENTS WITH B CELL MALIGNANCIES \n* VERASTEM INC - DUVELISIB IS BEING STUDIED IN OTHER HEMATOLOGIC MALIGNANCIES INCLUDING PERIPHERAL T CELL LYMPHOMA \n* VERASTEM INC - PLANS TO SUBMIT NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR DUVELISIBâ€‹ DURING Q1 2018 \n* VERASTEM INC - DUVELISIB ALONE, ANTI-PD-1 ALONE AND ANTI-OX40 ALONE EACH INDUCED TUMOR GROWTH DELAY \n* VERASTEM INC - WHEN DUVELISIB AND ANTI-PD-1 WERE COMBINED, STRONG ANTI-TUMOR SYNERGY WAS OBSERVED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-26T22:34:00.000+02:00", "crawled": "2018-01-26T22:51:39.011+02:00", "highlightTitle": ""}